Apr 30, 2018 - Four pharma/biotech companies are set to release earnings report on May 1. Let's take a look into how the companies are placed ahead of the upcoming results.
Apr 30, 2018 - Incyte (INCY) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to earnings beat.
Apr 27, 2018 - Incyte (INCY) is likely to beat on earnings when it reports first-quarter results on May 1 driven by strong Jakafi sales.
Apr 25, 2018 - The biotech sector grabbed headlines last week as a couple of biotechs reported results while few others came out with pipeline updates.
Apr 25, 2018 - Three biotechs reported devastating clinical trial failures this month. Here are the important takeaways.
Apr 25, 2018 - Lilly's first-quarter results looked good. Is it time to buy the big pharma stock?
Apr 24, 2018 - Eli Lilly (LLY) beats estimates for both earnings and sales in Q1 and raises guidance for 2018. Shares rise in pre-market trading.
Apr 20, 2018 - Highly anticipated events expected in the weeks ahead could set these three biotechs up for long-term success.
Apr 20, 2018 - Lilly's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
Apr 16, 2018 - Incyte’s phase 3 Epacadostat trial wasn’t so hot, and stocks all across biotech are feeling the burn.